Sequenom, Provid Pharma to Co-Develop Small-Molecule Tx | GenomeWeb

NEW YORK, April 10 - Sequenom and Provid Pharmaceuticals today said they plan to co-develop small-molecule therapeutics based on cardiovascular targets discovered by Sequenom.
 
Terms of the deal call for privately held Provid to receive an equity investment and research funding, and to be eligible for milestones and royalties on any products that may arise.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.